{"title":"High-Frequency Chest Wall Oscillation in Acute Respiratory Failure With Bronchial Hypersecretion: A Randomized Controlled Trial.","authors":"Simone Ielo, Nicoletta Golfi, Luca Guidelli, Stefania Arniani, Matilde Vespi, Gabriella Tacconelli, Noemi Preziosi, Uberto Maccari, Teresa Renda, Raffaele Scala","doi":"10.1016/j.chest.2026.10.007","DOIUrl":"https://doi.org/10.1016/j.chest.2026.10.007","url":null,"abstract":"<p><strong>Background: </strong>Airway secretion retention is common in patients with acute respiratory failure (ARF), particularly in those requiring noninvasive respiratory support (NIRS). High-frequency chest wall oscillation (HFCWO) may improve airway clearance but critical care evidence remains limited.</p><p><strong>Research question: </strong>Does adding HFCWO to standard care improve clinical outcomes in patients with bronchial hypersecretion and ARF requiring NIRS?</p><p><strong>Study design and methods: </strong>We conducted a single-center randomized controlled trial in a RICU. Patients with ARF requiring NIRS, including high-flow nasal cannula (HFNC) and/or noninvasive ventilation (NIV), bronchial hypersecretion, and ineffective cough (peak cough expiratory flow <270 L/min) were randomized 1:1 to HFCWO plus standard care or standard care alone. The primary endpoint was therapeutic bronchoscopy. Secondary endpoints included hospital length of stay (LOS), RICU-LOS, NIRS duration, endotracheal intubation and mortality. Outcomes were analyzed using unadjusted and adjusted models accounting for age, sex, and main cause of hospitalization.</p><p><strong>Results: </strong>Eighty-eight patients were enrolled (44 HFCWO, 44 control), with comparable baseline characteristics. Bronchoscopy was required in 6 patients (13.6%) versus 14 (31.8%) (unadjusted p=0.042); after adjustment the association did not retain statistical significance (adjusted OR 0.336, 95% CI 0.111-1.021; p=0.055). Secondary outcomes, analyzed without correction for multiple testing, are exploratory. Hospital stay (12 [10-15.5] vs 16.5 [13-21] days) and RICU stay (8 [7-10.5] vs 12 [9-17] days) were shorter, with adjusted reductions of 4.5 and 3.6 days. HFNC duration was shorter (6 [4-8] vs 9.5 [6-11.5] days) and remained significant after adjustment, whereas the reduction in NIV duration did not (adjusted p=0.166). No patient required intubation and mortality did not differ.</p><p><strong>Interpretation: </strong>In this exploratory trial, HFCWO did not significantly reduce the need for therapeutic bronchoscopy after adjustment. Associated reductions in LOS and HFNC duration are hypothesis-generating and require confirmation in adequately powered multicenter trials.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov: NCT05751707; Tuscany Ethics Committee (Protocol: 21987-10/17/2022).</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.8,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChestPub Date : 2026-10-12DOI: 10.1016/j.chest.2026.10.001
Christina K Rapp, Moritz Herkner, Victoria S E Crippa, Kataryzna Michel, Nurlan Dauletbaev, Ferdinand Guerth, Moniek van de Loo, Niels W Rutjes, Silvia Castillo-Corullón, Nazan Cobanoglu, Petra Kaiser-Labusch, Ulrich M Zissler, Simone Reu-Hofer, Nicolaus Schwerk, Florian Gothe, Matthias Griese
{"title":"Dominant lung involvement and heterozygous IFIH1 variants.","authors":"Christina K Rapp, Moritz Herkner, Victoria S E Crippa, Kataryzna Michel, Nurlan Dauletbaev, Ferdinand Guerth, Moniek van de Loo, Niels W Rutjes, Silvia Castillo-Corullón, Nazan Cobanoglu, Petra Kaiser-Labusch, Ulrich M Zissler, Simone Reu-Hofer, Nicolaus Schwerk, Florian Gothe, Matthias Griese","doi":"10.1016/j.chest.2026.10.001","DOIUrl":"https://doi.org/10.1016/j.chest.2026.10.001","url":null,"abstract":"<p><strong>Background: </strong>Heterozygous gain-of-function (GoF) variants in IFIH1 are associated with rare autoinflammatory diseases characterized by heightened interferons-stimulated gene (ISG) signatures. These include Aicardi-Goutières syndrome, presenting with slowly progressive spastic paraparesis of the lower limbs, intracerebral calcifications, and neuroinflammation, and Singleton-Merten syndrome, defined by tooth loss, bone demineralization, and vascular calcification.</p><p><strong>Research question: </strong>Do rare IFIH1 GoF variants contribute to an interstitial lung disease phenotype, thereby expanding the spectrum of IFIH1-related disorders?</p><p><strong>Study design and methods: </strong>Among 559 children with interstitial lung disease (chILD) and exome sequencing as part of their diagnostic work-up, 12 rare heterozygous IFIH1 variants were identified. Of these, 10 were missense variants of unknown significance, which were functionally assessed in vitro using luciferase assay and ISG-expression profiling. Genome-wide RNA analysis was performed on available patient samples to explore broader transcriptional effects.</p><p><strong>Results: </strong>Four variants with increased basal IFNβ transcription in vitro and elevated ISG expression in vivo indicating GoF behaviour were identified. Disease severity correlated with GoF potential of the respective variant. Two patients harbouring IFIH1 variants with strong GoF activity displayed multisystem involvement and died from respiratory failure at 3 and 4 months of age, respectively. Two additional patients showed milder phenotypes with chronic lung disease stabilizing by the age of 8 and 10 years, respectively. Lung biopsies showed alveolar hypoplasia and alveolar macrophage pneumonia (=desquamative interstitial pneumonia) of varying severity.</p><p><strong>Interpretation: </strong>We report a dominant interstitial lung disease phenotype in individuals harbouring novel IFIH1 variants, expanding IFIH1-related disease to the group of type I interferonopathies with pulmonary manifestations like STING-associated vasculopathy with onset in infancy (SAVI) and COPA syndrome.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.8,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChestPub Date : 2026-10-10DOI: 10.1016/j.chest.2026.10.003
Ayşe Aşık, Muhterem Duyu, Saime Hacer Özdemir Dağhan, Pelin Pehlivan, Burçin Türkmen, Nergiz Alçınkaya Sevinç, Yasemin Tüfekçi, Büşra Özyıldırım, Selin Yıldız Sametoğlu, Yonca Bulut
{"title":"Effectiveness of Continuous Automatic Endotracheal Cuff Pressure Monitoring in Preventing Ventilator-Associated Pneumonia in the Pediatric Intensive Care Unit: A Randomized Controlled Trial.","authors":"Ayşe Aşık, Muhterem Duyu, Saime Hacer Özdemir Dağhan, Pelin Pehlivan, Burçin Türkmen, Nergiz Alçınkaya Sevinç, Yasemin Tüfekçi, Büşra Özyıldırım, Selin Yıldız Sametoğlu, Yonca Bulut","doi":"10.1016/j.chest.2026.10.003","DOIUrl":"https://doi.org/10.1016/j.chest.2026.10.003","url":null,"abstract":"<p><strong>Background: </strong>Ventilator-associated pneumonia (VAP) is a major healthcare-associated infection in critically ill children, primarily driven by microaspiration around the endotracheal tube cuff.</p><p><strong>Research question: </strong>Does continuous automatic cuff pressure monitoring (CACPM) reduce the incidence of VAP compared to intermittent manual cuff pressure monitoring (IMCPM) in critically ill pediatric patients requiring mechanical ventilation?</p><p><strong>Study design and methods: </strong>In this open-label, randomized controlled superiority trial, pediatric patients requiring mechanical ventilation for ≥48 hours were randomly assigned (1:1) to either CACPM or IMCPM. The target cuff pressure was strictly maintained at 20-25 cmH<sub>2</sub>O. The primary outcome was the proportion of patients developing VAP within 28 days following intubation, evaluated in the intention to treat population. Secondary outcomes included time to VAP diagnosis and target pressure compliance. Statistical approaches included Kaplan-Meier survival analysis and multivariable Cox proportional hazard regression.</p><p><strong>Results: </strong>Among 241 randomized patients, ITT analysis showed lower VAP with CACPM than IMCPM (13.3% vs 24.0%; risk difference, -10.6 percentage points; 95% CI, -20.3 to -0.8; P=0.034), with similar PP findings (15.0% vs 26.6%; P=0.044). ITT incidence density was 15.7 vs 27.1 per 1,000 ventilator-days (IRR, 1.73; 95% CI, 0.94-3.18; P=0.080). Unadjusted time-to-VAP was nonsignificant (HR, 1.80; 95% CI, 0.976-3.321; P=0.060), whereas adjusted Cox analysis narrowly indicated a higher VAP hazard with IMCPM (HR, 1.90; 95% CI, 1.024-3.510; P=0.042). Target-pressure compliance was higher with CACPM (P<0.001).</p><p><strong>Interpretation: </strong>CACPM significantly reduces the proportion of critically ill pediatric patients developing VAP compared with IMCPM. This preventive effect appears directly linked to improved target pressure compliance, suggesting that automated regulation could be a valuable addition to pediatric VAP prevention strategies.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov, NCT05918172.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.8,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149167987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChestPub Date : 2026-10-09DOI: 10.1016/j.chest.2026.08.058
Adrien Cottu, Irene Mattioli, Matthieu Groh, Xavier Puéchal, Allyson Egan, Roberto Padoan, Luisa Brussino, Jan Schroeder, Camille Taillé, Maxime Samson, Pascal Cathébras, Francesco Cinetto, Halil Yildiz, Gregory Pugnet, Pierre Chauvin, Stéphane Jouneau, Elisabeth Diot, Sarah Nicolas, François Lifermann, Jean-Philippe Martellosio, Laurent Guilleminault, Yann Nguyen, Claire De Moreuil, Philippe Guilpain, Vincent Cottin, Luca Moroni, Paolo Delvino, Franco Franceschini, Edoardo Conticini, Claudia Crimi, Gianluca Moroncini, Milena Bond, Laura Moi, David Jayne, Augusto Vaglio, Colas Tcherakian, Giacomo Emmi, Benjamin Terrier
{"title":"Switching from mepolizumab to benralizumab in eosinophilic granulomatosis with polyangiitis (EGPA).","authors":"Adrien Cottu, Irene Mattioli, Matthieu Groh, Xavier Puéchal, Allyson Egan, Roberto Padoan, Luisa Brussino, Jan Schroeder, Camille Taillé, Maxime Samson, Pascal Cathébras, Francesco Cinetto, Halil Yildiz, Gregory Pugnet, Pierre Chauvin, Stéphane Jouneau, Elisabeth Diot, Sarah Nicolas, François Lifermann, Jean-Philippe Martellosio, Laurent Guilleminault, Yann Nguyen, Claire De Moreuil, Philippe Guilpain, Vincent Cottin, Luca Moroni, Paolo Delvino, Franco Franceschini, Edoardo Conticini, Claudia Crimi, Gianluca Moroncini, Milena Bond, Laura Moi, David Jayne, Augusto Vaglio, Colas Tcherakian, Giacomo Emmi, Benjamin Terrier","doi":"10.1016/j.chest.2026.08.058","DOIUrl":"https://doi.org/10.1016/j.chest.2026.08.058","url":null,"abstract":"<p><strong>Background: </strong>Eosinophilic granulomatosis with polyangiitis (EGPA) is an ANCA-associated vasculitis characterized by eosinophilic asthma and ENT involvement. Both mepolizumab and benralizumab have demonstrated efficacy in EGPA and are now considered front-line options. In patients who do not respond to mepolizumab, benralizumab may be a valuable alternative owing to its enhanced depletion of eosinophils. We assessed the efficacy for and safety of switching from mepolizumab to benralizumab in EGPA.</p><p><strong>Research question: </strong>Is benralizumab effective and safe in EGPA patients after mepolizumab failure, given its enhanced depletion of eosinophil?</p><p><strong>Study design and methods: </strong>We conducted a retrospective European multicenter study including 68 adult EGPA patients who received benralizumab after mepolizumab failure. Complete (CR) and partial (PR) response were defined as BVAS=0, with prednisone ≤4 mg/day and > 4 mg/day, respectively.</p><p><strong>Results: </strong>Median benralizumab follow-up period was 28 [20-39] months. CR and PR were achieved in 32% and 25% of patients, and maintained at last follow-up in 19% and 16%. Median time to CR was 6 [4-12] months. Forced expiratory volume in one second improved from 73% to 79%, and 38% of patients discontinued glucocorticoids. Vasculitis flares occurred in six patients. Primary mepolizumab failure was associated with lower CR rates (OR 0.19, 95% CI 0.06-0.60). Benralizumab was discontinued in 18% due to persistent respiratory symptoms. Adverse events occurred in five patients, including two severe SARS-CoV-2 infections.</p><p><strong>Interpretation: </strong>In EGPA patients with persistent respiratory manifestations after mepolizumab failure, switching to benralizumab could represent a valuable option, improving lung function and reducing glucocorticoid use. Further prospective studies are needed to optimize sequencing and patient selection.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.8,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149147272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChestPub Date : 2026-10-06DOI: 10.1016/j.chest.2026.09.099
Ophir Freund, Frederik Trinkmann, Shahar Koppelman, Konstantina Kontogianni, Inbar Yacoby Halevi, Doron Cohn-Schwartz, Nimrod Urtreger, Ariel Malloul, Eyal Kleinhendler, Amir Bar-Shai
{"title":"Changes in Small Airway Function After Dupilumab Initiation for Type 2 COPD: A Prospective Multicenter Study.","authors":"Ophir Freund, Frederik Trinkmann, Shahar Koppelman, Konstantina Kontogianni, Inbar Yacoby Halevi, Doron Cohn-Schwartz, Nimrod Urtreger, Ariel Malloul, Eyal Kleinhendler, Amir Bar-Shai","doi":"10.1016/j.chest.2026.09.099","DOIUrl":"10.1016/j.chest.2026.09.099","url":null,"abstract":"","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.8,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChestPub Date : 2026-10-05DOI: 10.1016/j.chest.2026.09.098
Freda Yang, Dominic C Marshall, Imran Howell, Timothy S C Hinks, Kian Fan Chung, Ian D Pavord, David J Jackson, Chloe I Bloom
{"title":"Exacerbation trajectories in biologic-eligible severe asthma patients.","authors":"Freda Yang, Dominic C Marshall, Imran Howell, Timothy S C Hinks, Kian Fan Chung, Ian D Pavord, David J Jackson, Chloe I Bloom","doi":"10.1016/j.chest.2026.09.098","DOIUrl":"https://doi.org/10.1016/j.chest.2026.09.098","url":null,"abstract":"<p><strong>Background: </strong>Asthma biologics are highly effective in reducing exacerbations. Improvement in exacerbations after biologic initiation is often attributed to treatment effect.</p><p><strong>Research question: </strong>What proportion of biologic-eligible severe asthma patients improve without biologic therapy, and what characterises those who remain frequent exacerbators?</p><p><strong>Study design and methods: </strong>Biologic-naïve adults with severe asthma were identified in nationwide UK electronic medical records. Year 0 was defined as the first year patients met severe asthma criteria with ≥3 systemic corticosteroid-treated exacerbations (biologic-eligible). Post-eligibility exacerbation trajectories were identified using longitudinal k-means. Sensitivity analyses included alternative k and a lower exacerbation threshold (≥2/year). Covariates included the highest blood eosinophil count, inhaled corticosteroid (ICS) dose and comorbidities.</p><p><strong>Results: </strong>Among 10,078 biologic-eligible adults (median age 51 years; 71% female), we identified three exacerbation trajectories: (1) Remitting-stable (70%, n=7,091), with sustained improvement to <3 exacerbations/year even though ICS reduced after peak exacerbation year; (2) Chronic-frequent (20%, n=1,969), with persistently frequent exacerbations (median 5/year); (3) Refractory-frequent (10%, n=1,018), with high ongoing oral corticosteroid exposure (median >10 courses/year). Results were consistent across sensitivity analyses. Remitting-stable patients were least likely to have bronchiectasis but were otherwise similar in demographics and allergic comorbidities. Blood eosinophil count was higher in the chronic-frequent group (Year 0 median 0.30×10<sup>9</sup>/L) compared with remitting-stable (0.23×10<sup>9</sup>/L) and refractory-frequent groups (0.21×10<sup>9</sup>/L, p<0.001); this was evident several years before meeting biologic exacerbation criteria.</p><p><strong>Interpretation: </strong>Over two-thirds of biologic-eligible patients improved with standard care alone. Chronic-frequent exacerbators had higher blood eosinophil counts, even years before meeting biologic criteria, suggesting a distinct disease phenotype.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.8,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChestPub Date : 2026-10-05DOI: 10.1016/j.chest.2026.09.096
Paul J Critser, Usha S Krishnan, Catherine M Avitabile, Andrea L Jones, Benjamin S Frank, Dunbar D Ivy, Emily P Williams, Rachel T Sullivan, Eric D Austin, Dephine Yung, Stephanie S Handler, Edward Kirkpatrick, Mary P Mullen, Claire Parker, Megan Griffiths, Patrick D Evers, Meredith J O'Neil, Neelam D Bhatt, Rachel Capote, Erika B Rosenzweig, Nidhy P Varghese
{"title":"Sotatercept in Pediatric Pulmonary Hypertension: Experience From the Pediatric Pulmonary Hypertension Network.","authors":"Paul J Critser, Usha S Krishnan, Catherine M Avitabile, Andrea L Jones, Benjamin S Frank, Dunbar D Ivy, Emily P Williams, Rachel T Sullivan, Eric D Austin, Dephine Yung, Stephanie S Handler, Edward Kirkpatrick, Mary P Mullen, Claire Parker, Megan Griffiths, Patrick D Evers, Meredith J O'Neil, Neelam D Bhatt, Rachel Capote, Erika B Rosenzweig, Nidhy P Varghese","doi":"10.1016/j.chest.2026.09.096","DOIUrl":"10.1016/j.chest.2026.09.096","url":null,"abstract":"<p><strong>Background: </strong>Sotatercept, a ligand trap for transforming growth factor-beta family members, has been shown to improve exercise capacity and decrease pulmonary vascular resistance in adults with pulmonary arterial hypertension. Limited data exist describing the use of sotatercept in children with pulmonary hypertension (PH).</p><p><strong>Research question: </strong>What is the safety and efficacy of sotatercept as add-on therapy in children with PH?</p><p><strong>Study design and methods: </strong>This is a multicenter, retrospective study of children and young adults ≤ 21 years of age with pediatric PH treated by programs in the Pediatric Pulmonary Hypertension Network and institutional registries. Demographic data and clinical characteristics before and after sotatercept initiation were collected.</p><p><strong>Results: </strong>A total of 66 patients received sotatercept as add-on therapy for a median duration of 323 days (interquartile range, 239-500). Of these, 40 patients (60%) were female, with a median age of 15.3 years (range, 3.0-21.0) at initiation of sotatercept; 61 patients (92%) had group 1 PH. World Health Organization functional class improved in 51% and did not worsen in any patients (P < .0001). Patients experienced significant improvement in 6-minute walk distance (median, 31 m; P = .0003, n = 40), N-terminal pro-B-type natriuretic peptide (median decrease, 378 pg/mL; P < .0001; n = 26), mean pulmonary artery pressure (median decrease, 17 mm Hg; P < .0001; n = 21), and pulmonary vascular resistance (median decrease, 4.4 WUi; P = .0011; n = 21). Parenteral prostacyclin was weaned or discontinued in 13 of 38 patients. Adverse events occurred in 33 patients (50%), with bleeding in 15 (23%). No patients had escalation of PH therapy, were hospitalized for clinical worsening, underwent lung transplant, or died.</p><p><strong>Interpretation: </strong>Our results show that patients with pediatric PH treated with sotatercept as add-on therapy demonstrated improvement in functional class and other PH disease indicators and were generally well tolerated.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.8,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChestPub Date : 2026-10-05DOI: 10.1016/j.chest.2026.09.100
Shilpa Sridhar, Keegan Riggs, Amanda Kaley, Dawn C Newcomb, Dharini M Bhammar, Rachel Meislin, Dawn L DeMeo, Sonali Bose, Jing Gennie Wang
{"title":"From Menarche to Menopause: A Narrative Review of Female Reproductive Milestones and Risk of Chronic Airway Disease.","authors":"Shilpa Sridhar, Keegan Riggs, Amanda Kaley, Dawn C Newcomb, Dharini M Bhammar, Rachel Meislin, Dawn L DeMeo, Sonali Bose, Jing Gennie Wang","doi":"10.1016/j.chest.2026.09.100","DOIUrl":"https://doi.org/10.1016/j.chest.2026.09.100","url":null,"abstract":"<p><strong>Topic importance: </strong>Female reproductive factors are underrecognized determinants of lifelong respiratory health. This narrative review examines relationships between reproductive milestones and chronic airway disease risk.</p><p><strong>Review findings: </strong>Early menarche is associated with reduced adult lung function and a higher incidence of asthma. Polyendocrine metabolic ovarian syndrome is also associated with increased asthma risk, particularly in obese individuals, through sex hormone dysregulation, metabolic dysfunction, and chronic low-grade inflammation. Adverse pregnancy outcomes are associated with lower lung function and heightened future asthma and chronic obstructive pulmonary disease (COPD) susceptibility, potentially from persistent systemic inflammation, endothelial injury, and oxidative stress beyond the perinatal period. Effects of exogenous sex hormones on the airways are complex and context-dependent. Hormonal contraception may reduce asthma risk in lean females by stabilizing estrogen and progesterone fluctuations, but increase risk in obesity, as exogenous estrogen can amplify airway inflammation. Similarly, effects of menopause hormone therapy (MHT) vary by formulation, timing of initiation, and use duration. Estrogen-only MHT - particularly when started at younger ages, before menopause, or used for longer duration - may increase asthma risk. Early menopause is linked to accelerated lung function decline, higher asthma incidence among those with obesity, and increased COPD risk.</p><p><strong>Summary: </strong>Female reproductive factors may influence susceptibility to chronic airway disease, although these relationships involve multiple pathways, with obesity as a major confounder. A dedicated life-course cohort with deep phenotyping and hormone profiling is needed to elucidate how reproductive exposures, sex hormones, metabolic determinants and other susceptibility factors interact to shape respiratory outcomes in females.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.8,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ChestPub Date : 2026-10-05DOI: 10.1016/j.chest.2026.09.090
Fei He, Yuan Xu, Binghua Tu, Yuhang Liu, Weimin Ye, Yiming Zeng, Charles A Powell
{"title":"Lung Cancer Screening Beyond Smoking-Based Eligibility: Evidence, Limits, and Lessons From China.","authors":"Fei He, Yuan Xu, Binghua Tu, Yuhang Liu, Weimin Ye, Yiming Zeng, Charles A Powell","doi":"10.1016/j.chest.2026.09.090","DOIUrl":"10.1016/j.chest.2026.09.090","url":null,"abstract":"<p><strong>Topic importance: </strong>Low-dose CT (LDCT) screening lowers lung cancer mortality in populations with substantial cumulative tobacco exposure; this conclusion rests on 2 adequately powered randomized controlled trials. Whether the same benefit extends to populations with different risk profiles remains unresolved, particularly in China, where a substantial share of lung cancers arise in individuals without a substantial smoking history.</p><p><strong>Review findings: </strong>This review develops 3 linked arguments rather than surveying the field exhaustively. First, stage shift and risk enrichment are necessary but not sufficient; a concurrent reduction in advanced-stage incidence is the more reliable signal of benefit. Second, risk prediction models built on tobacco-exposed cohorts are least dependable in individuals without substantial smoking history, precisely where expanding eligibility relies on them most. Third, judging evidentiary sufficiency requires an explicit framework that treats sufficiency as a continuum, rather than as a binary between a randomized trial and nothing. Chinese programs illustrate all 3 at scale: LDCT scan can be delivered broadly and can enrich early stage detection, but it has still not reduced lung cancer mortality with acceptable harm. Stage-shift findings remain vulnerable to lead-time bias, length bias, and overdiagnosis, and recent data from China and South Korea suggest that diffusion of LDCT scan into populations at average risk may enlarge overdiagnosis more than net benefit.</p><p><strong>Summary: </strong>For populations without substantial smoking history, eligibility decisions should rest on prospective evidence of reduced advanced-stage incidence rather than stage-shift enrichment alone; expansion belongs within disciplined prospective evaluation.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.8,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}